EP Patent

EP1859793B1 — Novel combinational use of a sulfonamide compound in the treatment of cancer

Assigned to Eisai R&D Management Co Ltd · Expires 2011-04-20 · 15y expired

What this patent protects

A pharmaceutical composition, a kit and a method for the treatment of cancer which are characterized in that a sulfonamide compound is used in combination with a substance having an EGF inhibitory activity.

USPTO Abstract

A pharmaceutical composition, a kit and a method for the treatment of cancer which are characterized in that a sulfonamide compound is used in combination with a substance having an EGF inhibitory activity.

Drugs covered by this patent

Patent Metadata

Patent number
EP1859793B1
Jurisdiction
EP
Classification
Expires
2011-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.